Abstract 6044: Primary Left Main Percutaneous Coronary Intervention in a Hemophilia B Patient Presenting with Cardiogenic Shock
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.6044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Muhammad Saad und 2 weiteren Autor:innen.
Abstract (Originalsprache)
INTRODUCTION: As life expectancy in persons with hemophilia (PWH) approaches that of the general population, atherosclerotic cardiovascular disease has become increasingly prevalent. While PCI in PWH with acute coronary syndromes has been described, no prior case has reported left main PCI complicated by cardiogenic shock in a hemophilia B patient — requiring simultaneous management of life-threatening ischemia and severe hemorrhagic risk. PATIENT INFORMATION: The patient was a 62-year-old male with moderate hemophilia B (baseline factor IX activity 8%), prior coronary artery bypass grafting (LIMA to LAD; radial artery to RCA), hypertension, hyperlipidemia, and type 2 diabetes. He had a history of major bleeding after dental extractions without factor IX prophylaxis. CLINICAL FINDINGS & TIMELINE: He presented with acute chest pain and hemodynamic instability (blood pressure 86/50 mmHg, heart rate 110 bpm). Electrocardiogram showed deep ST-segment depression in V2-V6, I, and aVL with T-wave inversions. Troponin I was 7.25 ng/mL and CK-MB 7.7 ng/mL. DIAGNOSTIC ASSESSMENT & REASONING: Findings were consistent with NSTEMI and cardiogenic shock. Urgent coronary angiography via radial access revealed a 95% calcified left main stenosis with patent bypass grafts and incomplete circumflex filling via retrograde LAD collaterals. THERAPEUTIC INTERVENTION: Hematology was consulted emergently and recommended factor IX concentrate (7,000 IU) before antithrombotic therapy. The patient then received unfractionated heparin, eptifibatide, aspirin, and clopidogrel 600 mg. An intra-aortic balloon pump provided hemodynamic support. Left main PCI was performed with a 4.0 х 15 mm bare-metal stent, achieving 5% residual stenosis with immediate circumflex flow restoration. Post-procedurally, factor IX infusions targeted 100% activity for 72 hours, then twice-weekly infusions maintaining trough levels of 15-20% throughout the six-week dual antiplatelet therapy (DAPT) course. FOLLOW-UP, OUTCOMES & ADVERSE EVENTS: The patient achieved full clinical recovery and was discharged without bleeding or thrombotic complications during the DAPT period. DISCUSSION & SYNTHESIS: To our knowledge, this is the first reported case of successful primary left main PCI in a hemophilia B patient with cardiogenic shock. Success relied on four principles: emergent hematology-cardiology collaboration; pre-procedural factor IX repletion; radial access to reduce bleeding risk; and a post-procedural factor IX bridging protocol aligned with DAPT duration. Antithrombotic therapy must be individualized to balance thrombosis and hemorrhage in PWH. Bare-metal stenting limited DAPT exposure; however, polymer-free drug-coated stents with abbreviated DAPT may be superior in future cases. This case highlights the need for prospective registries and consensus guidelines for acute coronary syndromes in PWH.
Zitieren
APA
Saad, M., Jilani, M. H., & ARIF, I. (2026). Abstract 6044: Primary Left Main Percutaneous Coronary Intervention in a Hemophilia B Patient Presenting with Cardiogenic Shock. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.6044
Vancouver
Saad M, Jilani MH, ARIF I. Abstract 6044: Primary Left Main Percutaneous Coronary Intervention in a Hemophilia B Patient Presenting with Cardiogenic Shock. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.6044
BibTeX
@article{Saad2026,
author = {Saad, Muhammad and Jilani, Mohammad Hashim and ARIF, IMRAN},
title = {Abstract 6044: Primary Left Main Percutaneous Coronary Intervention in a Hemophilia B Patient Presenting with Cardiogenic Shock},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.6044}
}
EUVIMED